Search
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalIn late 2013, the first cases were identified in the Caribbean, and it has since spread to most of the Americas.[L48786] There are no approved treatments for active chikungunya virus infection. … caused by chikungunya virus.
Lisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigational[L48285] Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder [A2230] by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMefloquine
go.drugbank.com/drugs/DB00358ApprovedIt was approved by the FDA in 1989, and was first marketed by Hoffman Laroche. … The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 1963 until 1976.
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.
Trastuzumab
go.drugbank.com/drugs/DB00072ApprovedInvestigationalIn November 2023, trastuzumab was also approved by the EMA under the brand name Herwenda.[L49339] … Kanjinti (trastuzumab-anns)[L14135] and Hercessi[L52840] are other biosimilars approved by the FDA. In Canada, biosimilars ONTRUZANT[[L40303, L40308] and Adheroza[L52835] are approved.
Pidolic acid
go.drugbank.com/drugs/DB03088ApprovedInvestigationalPidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics … There are currently little to no medicines available that are clinically approved or marketed for employing pidolic acid as an active ingredient for any particular formal indication.
Margetuximab
go.drugbank.com/drugs/DB14967ApprovedInvestigational[A225751] The introduction of [trastuzumab] improved patient outcomes in HER2-positive breast cancer, but notably depended substantially on polymorphisms in the FcγRIIIA/CD16A receptor, whereby low affinity … Of the various subtypes of breast cancer, HER2-positive breast cancer is characterized by _ERBB2_ overexpression, a higher grade, a more aggressive phenotype, and a worse prognosis compared to HER2-negative
N-Acetylglucosamine
go.drugbank.com/drugs/DB00141ApprovedInvestigationalNutraceuticalThe N-acetyl derivative of glucosamine.
Synonyms: N-Acetylchitosamine, N-AcetylglucosamineMixtures: Cheon Shim Bo YunPhentermine
go.drugbank.com/drugs/DB00191ApprovedIllicitInvestigationalThis initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers … [A174370] Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L39544] It was fully approved by the FDA on May 25, 2023. … [L33359] Both drugs were inhibitors of SARS-CoV-2 3CL<sup>PRO</sup>, but nirmatrelvir has the advantage of being orally bioavailable.